RxDoctor Payments Data

Jay Tiongson, MD

Clinical Cardiac Electrophysiology · Mission Viejo, CANPI 1609082312

Payments from drug & device makers

$73,876in general payments, 2019–2025

Across 540 payments — averaging $136.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$22K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19K
  • Medtronic$15K
  • Abbott$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Biosense Webster, Inc.$3K
  • plus $6K from 21 others

What the payments were for

  • Consulting fees$2,2135%
  • Speaking & faculty fees$17,60441%
  • Travel & lodging$7,16017%
  • Food & beverage$16,20038%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,876 in reported general payments places this provider in the 65th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$842,781
Medicare patients
993
Services billed
7,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,225$1,320,861
MultaqDronedarone Hcl481$607,214
XareltoRivaroxaban204$218,873
Flecainide Acetate818$32,608
Amiodarone Hcl311$10,854
Dofetilide67$10,697
Propafenone Hcl ErPropafenone Hcl54$9,965
CorlanorIvabradine Hcl11$7,495
Diltiazem 12hr ErDiltiazem Hcl36$5,633
Metoprolol Succinate369$4,937
Propafenone Hcl56$4,180
Midodrine Hcl46$3,419
Mexiletine Hcl14$2,923
Eplerenone40$2,444
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$2,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$580$1,320,8611,225 claims
Sanofi-aventis U.S. LLCMultaq$220$607,214481 claims
Johnson & JohnsonXarelto$430$218,873204 claims
AmgenCorlanor$24$7,49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →